NCT05599945View on ClinicalTrials.gov

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Healthy VolunteersHepatic Steatosis
Interventions
DRUG

NNC0581-0001

Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

DRUG

Placebo (NNC0581-0001)

Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Trial Locations (2)

HA1 3UJ

Parexel CPRU, Level 7, Harrow

Parexel Research Unit, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY